For Pfizer, putting patients first guides its actions, informs its strategic decisions and unifies colleagues in every region and function across the company. Beatriz Faro, Regional President, Internal Medicine, International Developed Markets at Pfizer, explains how the company’s philosophy is taking the business forward…
What would you say have been the most significant developments in the pharmaceutical industry over the past 21 years?
The sequencing of the human genome at the turn of the 21st Century has transformed our understanding of disease and our ability to deliver care in a way that is specific and personal to each individual patient. As a result, personalised medicine is set to reduce the burden of disease by targeting prevention and treatment more effectively – and in ways that better meet the individual needs of the patient.
This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.
Key learning points:
Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
Learn about ITM’s implementation journey and considerations when evaluating the technology
Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).
Don’t miss your chance to learn from experts in the industry –Register for FREE
Our 21 @ 21 Anniversary Supplement is just one of the many resources a free subscription to European Pharmaceutical Review provides. If you are already a subscriber, login to download the PDF.
Not yet a subscriber? Join our growing community of thousands of industry professionals and gain access to:
Bi-monthly issues in print and/or digital format
Case studies, whitepapers, webinars and industry-leading content
Breaking news and features
Our extensive online archive of over 8,500 articles and past issues
In addition – as has been widely documented – patent expiries and declining R&D productivity have prompted the pharmaceutical industry to change its operating model significantly over the past couple of decades. As part of this process, the industry has progressively tailored its pipeline to specialty medicines and biologics targeted for high unmet medical needs. Locating research units in bioscience hotspots or innovation clusters has also enabled industry scientists to work closely with external researchers and clinicians in a much more open and collaborative way.
How has your company evolved to meet these challenges?
Patients inspire us and the work we do. Putting patients first guides our actions, informs our strategic decisions and unifies colleagues in every region and function across the company.
Six years ago, we implemented a longterm strategy to position Pfizer for a return to top-line growth. Since then, we have worked to shape the quality of the assets in our pipeline by sharpening our focus on core research areas that give us the best opportunity for scientific and commercial success, so helping us to improve the lives of patients. These areas include biosimilars, inflammation and immunology, metabolic disease and cardiovascular risks, neuroscience, oncology, rare diseases and vaccines.
We believe that collaboration is the key to whatever we accomplish. We undertake to evaluate any opportunities likely to improve our clinical expertise and consequently have a wide range of ambitious and effective scientific partnerships across the world. Each of these focus on the promotion of scientific excellence and, ultimately, on the discovery of breakthrough therapies that meet unmet medical needs.
For example, we received breakthrough therapy designation from the US Food and Drug Administration (FDA) for a haemophilia gene therapy being developed in partnership with SPARK Therapeutics in 2016. In the same year we acquired Bamboo Therapeutics – a privately held biotechnology company focused on developing gene therapies for the potential treatment of patients with certain rare diseases, such as Duchenne muscular dystrophy and Friedreich’s ataxia.
We also have a collaboration with 23andMe, which includes studies to aid understanding of depression, dysmenorrhea and the genetic heterogeneity of lupus and inflammatory bowel disease. Through efforts such as this, we believe we are poised Beatriz Faro, Regional President, Internal Medicine International, Pfizer to potentially usher in a new era of patient care defined by targeted research methods and ultimately better patient outcomes.
Looking ahead to the next few years, what do you think are likely to be the main opportunities and challenges affecting the industry?
I think the realities of an ageing population and the burden of chronic diseases, as well as advances in treatment and technology, are likely to encourage growth within the industry. However, providing sustainable access to healthcare will be a significant global challenge. As a result, payers will continue to impose cost constraints and scrutinise the value medicines offer far more carefully. Companies will be expected to use real-world data to demonstrate that new treatments are clinically and economically superior to existing therapies.
In addition, healthcare has undoubtedly become more patient centric. The digital revolution has empowered patients, enabling them to secure the information they need to make informed decisions about their treatment options and this has dramatically affected the ways in which the industry communicates with them.
Finally, the convergence of IT and healthcare is impacting the pharmaceutical model. Big data and mobile health are starting to transform healthcare and diagnostics, with organisations such as Apple and Google encroaching on territory that was traditionally the reserve of pharmaceutical companies. Smartphones, sensors, wearables, apps and so on are all collecting remote, objective data in real time and so better measuring patient outcomes.
How is your company preparing for these developments?
The success of our business begins and ends with the health of our patients. This means continuing to strengthen our understanding of patient experiences, engaging in strategic partnerships and investing in the most advanced technology that will help to drive innovation in public health.
We continue to evolve the way we engage with patients, their families and the healthcare community around the world. Through various public health initiatives, we are working to bridge significant health gaps in patient education and care by equipping people with trusted information and tools that enable them to take a more active role in their healthcare.
By recognising that putting patients first is the only way healthcare companies can expect to thrive, we strive to be patientcentred in our thinking and action. We ask patients what they need and what they expect from any new therapy we plan to introduce.
For example, we have an exciting, firstof- its-kind research collaboration with IBM focused on Parkinson’s disease where we are developing a system of hundreds of remote sensors and mobile devices to provide realtime, around-the-clock disease symptom information. The ultimate goal is to obtain a better understanding of the progress of a patient’s disease and response to medication so informing treatment and clinical trial design, while also speeding the development of new therapeutic options.
We also believe that diversity is as crucial to creating a successful business as it is to building a vibrant culture. We therefore surround ourselves with colleagues of diverse backgrounds and abilities who can contribute unique viewpoints and perspectives to all aspects of the business, from drug development to marketing. This is a topic that is particularly close to my heart.
What would you say has been your company’s outstanding achievement (or achievements) of recent years, and what impact has this had on patients and potentially the industry in general?
Clearly, this is the positive impact we have had on people’s health. Our commitment at Pfizer is to ensure that individuals have the opportunity to lead healthier lives. While, for us, this starts with discovery and development of medicines, it is only made a reality when individuals everywhere have access to quality medicines and healthcare. Together, with partners around the world, progress has been made in advancing longer and healthier lives.
For example, our donation of an antibiotic used to treat blinding trachoma in partnership with the International Trachoma Initiative (ITI), as well as the implementation of the WHO-recommend SAFE strategy, played a pivotal role in eliminating trachoma as a public health problem in Morocco – obviously an impressive achievement.
Successful innovations in pharma are likely to increasingly rely on partnerships and collaborations between manufacturers, suppliers, academics, and a whole range of other companies and organisations. What do you look for in these relationships, and can you give an example of one that has worked particularly well for you?
We believe that working with others that have an interest in health and medicine contributes to better overall outcomes for patients, healthcare providers and healthcare systems. We foster collaboration to develop solutions for preventing disease, restoring health and keeping people well at all stages of their lives. This includes discovering and developing high-value therapies and working together to increase access to important medicines for greater numbers of people.
For example, we have a global strategic alliance with Merck KGaA to develop and commercialise an investigational drug as a potential treatment for multiple types of cancer. Together, we are forging a strong capability in immuno-oncology, an approach to treatment that rallies the body’s natural defences – and this was a new theory just a decade ago. We believe we are now well positioned to capitalise on what many believe will be the future of cancer treatment – immuno-oncology agents combined with more conventional therapies.
In addition, we have launched a global network of Pfizer innovation hubs in Berlin, London, New York, Stockholm, Sydney, Tel Aviv and Toronto in the past three years. These are dedicated to helping late-stage digital healthcare start-ups achieve their own goals by enabling them to grow and reach more patients and providers through collaboration with our mentors and partners. We are committed to our patients and believe that partnering and collaborating with others who share a similar purpose will accelerate the development of solutions to help improve lives.
Pfizer profile
Pfizer is one of the world’s premier innovative biopharmaceutical companies. Since 1849 we have been committed to helping people live longer, healthier lives and today, the medicines we produce save or improve lives. With the help of our research partners, we apply the latest science and technology to discover new therapies, actively collaborating with universities, governments, foundations and patient advocates, so that more people around the world have access to better health. We currently employ approximately 96,500 people, working across 46 countries and we reported full-year 2016 revenues of $52.8bn, reflecting 11% operational growth.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.